I-Mab remakes itself, with plans for Hong Kong listing, retinal R&D, and a new namenews2025-10-16T20:05:59+00:00October 16th, 2025|Endpoints News|
Pregene lands up to $1.52B deal with Kite for in vivo therapiesnews2025-10-16T19:25:26+00:00October 16th, 2025|Endpoints News|
Pfizer CEO says US must compete better against China, not block itnews2025-10-16T19:06:09+00:00October 16th, 2025|Endpoints News|
Obesity biotech Kailera gets $600M to start Phase 3 this yearnews2025-10-14T11:06:10+00:00October 14th, 2025|Endpoints News|
Three big questions ahead of third-quarter pharma earningsnews2025-10-13T20:09:50+00:00October 13th, 2025|Endpoints News|
WuXi companies left out of latest version of Biosecure Actnews2025-10-10T19:20:46+00:00October 10th, 2025|Endpoints News|
Chinese biotechs work on cheaper alternatives to $2M Zolgensmanews2025-10-09T14:00:08+00:00October 9th, 2025|Endpoints News|
Eccogene files for Hong Kong IPO to back development of GLP-1 pipelinenews2025-10-08T14:50:39+00:00October 8th, 2025|Endpoints News|
In $2B biobucks pact, Zenas snags MS drug that Biogen returned to InnoCarenews2025-10-08T11:24:07+00:00October 8th, 2025|Endpoints News|
Biotech IPOs in Hong Kong far outpace the US, driven by China’s buzzy biotech sectornews2025-10-02T14:39:04+00:00October 2nd, 2025|Endpoints News|
